A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
Part of paid clinical trials in Andalusia, Alabama.
- Sponsor
- Novartis Pharmaceuticals
- Study ID
- NCT06857955
- Phase
- PHASE2
- Status
- Active Not Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Saline — OTHER0.9% sodium chloride saline solution
- QCZ484 — DRUGSolution of Injection
Study Details
The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension
Key Dates
- Start date
- Mar 26, 2025
- Status verified
- May 2026
- Primary completion
- Jan 29, 2027
- Completion
- Apr 5, 2028
Study Design
- Enrollment
- 385 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- OTHER
Arms
- Placebo Comparator: Placebo ControlPlacebo
- Experimental: QCZ484 Dose 1QCZ484 Dose 1 solution for injection
- Experimental: QCZ484 Dose 2QCZ484 Dose 2 solution for injection
- Experimental: QCZ484 Dose 3QCZ484 Dose 3 solution for injection
- Experimental: QCZ484 Dose 4QCZ484 Dose 4 solution for injection
- Experimental: QCZ484 Dose 5QCZ484 Dose 5 solution for injection
Primary Outcome Measure
Change in Mean 24hr SBP by ABPM [ Time Frame: Baseline, Month 3 ]
Locations (72)
Find similar trials in Andalusia, AL
By condition
By specialty
Related Studies
- Diabetes and Heart Disease Risk in BlacksRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Effect of Electro-Acupuncture on Blood PressureRecruiting · University of California, Irvine · Irvine, California
- Metabolic Effects of Angiotensin-(1-7)PHASE1 · Recruiting · Vanderbilt University · Nashville, Tennessee
- : Vascular Function in Health and DiseasePHASE1 · Recruiting · Russell Richardson · Salt Lake City, Utah